MedPath

ITM Solucin GmbH

🇩🇪Germany
Ownership
Private
Employees
-
Market Cap
-
Website
https://www.itm-radiopharma.com/home

Clinical Trials

24

Active:20
Completed:0

Trial Phases

2 Phases

Phase 1:17
Phase 3:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials

Phase 1
17 (70.8%)
Phase 3
7 (29.2%)

A trial to determine the dose, and evaluate the safety and pharmacokinetics of lutetium Lu 177 edotreotide in children with somatostatin receptor-positive (SSTR+) tumors

Phase 1
Not yet recruiting
Conditions
Pediatric patients two years of age and above with somatostatin receptor positive (SSTR-positive) solid tumors or lymphoma, recurrent/refractory to at least one prior line of therapy
First Posted Date
2025-03-19
Last Posted Date
2025-04-24
Lead Sponsor
ITM Solucin GmbH
Target Recruit Count
12
Registration Number
2024-512831-66-00
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy

🇪🇸

Hospital Universitari Vall D Hebron, Barcelona, Spain

🇪🇸

Hospital General Universitario Gregorio Maranon, Madrid, Spain

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Phase 3
Active, not recruiting
Conditions
Neuroendocrine Tumors
Interventions
Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
Drug: CAPTEM (Capecitabine and Temozolomide)
Other: Amino-Acid Solution
Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
First Posted Date
2021-06-09
Last Posted Date
2025-05-29
Lead Sponsor
ITM Solucin GmbH
Target Recruit Count
259
Registration Number
NCT04919226
Locations
🇺🇸

Stanford Cancer Center, Palo Alto, California, United States

🇺🇸

University of Colorado Hospital, Nuclear Medicine, Aurora, Colorado, United States

🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 39 locations

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Phase 3
Active, not recruiting
Conditions
Neuroendocrine Tumors
Interventions
First Posted Date
2017-02-09
Last Posted Date
2025-05-30
Lead Sponsor
ITM Solucin GmbH
Target Recruit Count
309
Registration Number
NCT03049189
Locations
🇺🇸

Banner Health d.b.a. Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 49 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.